OnKure Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
OKUR$3.19+11.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands, except share data)
| Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Stockholders' | ||||||||||
| Convertible Preferred Stock · Class A Common stock · Class B Common stock · Paid-In · Accumulated · (Deficit)/ | ||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Equity | ||||||||||
| Balance, December 31, 2023 | 6,840,620 | $129,825 | 313,747 | $— | — | $— | $209 | $(102,051) | $(101,842) | |
| Conversion of Convertible Preferred Stock for Class A and B Common Stock in connection with the Merger | (6,840,620) | (129,825) | 6,154,093 | 1 | 686,527 | — | 129,824 | — | 129,825 | |
| Issuance of Class A Common Stock in the Concurrent Financing, less issuance costs | — | — | 2,571,736 | — | — | — | 54,428 | — | 54,428 | |
| Issuance of common stock to former stockholders of Reneo Pharmaceuticals, Inc. in the reverse recapitalization | — | — | 3,343,604 | — | — | — | 65,499 | — | 65,499 | |
| Reverse recapitalization transaction costs of OnKure | — | — | — | — | — | — | (2,085) | — | (2,085) | |
| Issuance of Class A Common Stock for the conversion of Convertible Promissory Notes | — | — | 267,269 | 6,120 | 6,120 | |||||
| Issuance of Class A common stock for the settlement of restricted stock units | — | — | 7,700 | — | — | — | — | — | — | |
| Issuance of Class A Common Stock from the exercise of stock options | — | — | 2,476 | — | — | — | 26 | — | 26 | |
| Adjustment for fractional shares in the reverse recapitalization | — | — | (35) | — | — | — | — | — | — | |
| Share-based compensation | — | — | — | — | — | — | 4,530 | — | 4,530 | |
| Net loss | — | — | — | — | — | — | — | (52,673) | (52,673) | |
| Balance, December 31, 2024 | — | — | 12,660,590 | $1 | 686,527 | $— | $258,551 | $(154,724) | $103,828 | |
| Conversion of Class B Common Stock to Class A Common Stock | — | — | 686,527 | — | (686,527) | — | — | — | — | |
| Issuance of Class A Common Stock under the Employee Stock Purchase Plan | — | — | 107,930 | — | — | — | 240 | — | 240 | |
| Vesting of restricted stock units, net | — | — | 218,518 | — | — | — | — | — | — | |
| Share-based compensation | — | — | — | — | — | — | 11,633 | — | 11,633 | |
| Net loss | — | — | — | — | — | — | — | (59,517) | (59,517) | |
| Balance, December 31, 2025 | — | $— | 13,673,565 | $1 | — | $— | $270,424 | $(214,241) | $56,184 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.